The market for reproductive genetic testing historically been dominated by carrier screening but progress is being made in different methods, including non-invasive prenatal testing.
Natera's lead product, its Panorama test, screens for fetal abnormalities, including Down syndrome, Edwards syndrome and Turner syndrome, as well as severe organ abnormalities and fetal viability.
What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes.